Myriad Genetics (STU:MYD) LT-Debt-to-Total-Asset: 0.30 (As of Mar. 2026)

What is Myriad Genetics LT-Debt-to-Total-Asset?

Myriad Genetics STU:MYD +0.35% 49 LT-Debt-to-Total-Asset is 0.30 as of Mar. 2026. GuruFocus rates STU:MYD with a GF Score™ of 49/100 and a GF Value™ of €13.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Myriad Genetics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.30.

Myriad Genetics's long-term debt to total assets ratio increased from Mar. 2025 (0.15) to Mar. 2026 (0.30). It may suggest that Myriad Genetics is progressively becoming more dependent on debt to grow their business.

Myriad Genetics (STU:MYD) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Myriad Genetics LT-Debt-to-Total-Asset Related Terms

Myriad Genetics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Myriad Genetics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Myriad Genetics LT-Debt-to-Total-Asset Chart

Myriad Genetics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.11

0.12

0.29

Myriad Genetics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.15	0.13	0.28	0.29	0.30

49GF Score

Myriad Genetics Inc STU:MYD

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Myriad Genetics LT-Debt-to-Total-Asset Calculation

Myriad Genetics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	173.277	/	603.436
	=	0.29

Myriad Genetics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	176.806	/	582.75
	=	0.30

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.30 mean?

Myriad Genetics (STU:MYD) has a LT-Debt-to-Total-Asset of 0.30 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Myriad Genetics and its competitors.

Is Myriad Genetics' LT-Debt-to-Total-Asset too high?

Myriad Genetics' current LT-Debt-to-Total-Asset is 0.30. Overall, Myriad Genetics has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Myriad Genetics' LT-Debt-to-Total-Asset compare to FLGT and CSTL?

Myriad Genetics' LT-Debt-to-Total-Asset of 0.30 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Myriad Genetics and its competitors. Myriad Genetics's current LT-Debt-to-Total-Asset is 0.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Myriad Genetics stock overvalued right now?

Based on GuruFocus' analysis, Myriad Genetics (STU:MYD) is currently considered Possible Value Trap. The stock's GF Value™ is €13.20, compared to a current price of €5.11 — trading 61.3% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.30. Myriad Genetics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Myriad Genetics (STU:MYD), the current LT-Debt-to-Total-Asset is 0.30 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €5.11 is trading 61.3% below its estimated GF Value™ of €13.20. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

LT-Debt-to-Total-Asset: 0.30
GF Value™: €13.20 vs. price of €5.11 (61.3% below fair value)
GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies FLGT CSTL BDSX IMDX XGN BNR IDXG PRPO QUCY BIOQ TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Other Exchanges MYGN:USA 0K3W:UK MYD:Germany

Address 322 North 2200 West, Salt Lake City, UT, USA, 84116

Website https://www.myriad.com

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

49GF Score

Get the complete analysis for STU:MYD

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.11

Price

€13.20

GF Value

View STU:MYD Analysis

See LT-Debt-to-Total-Asset data for all stocks →